What is the management approach for an 11-year-old with fever, rash, leukocytosis, and elevated CRP?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 28, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of an 11-Year-Old with Fever, Rash, and Marked Leukocytosis

This child requires immediate hospital admission for urgent evaluation of multisystem inflammatory syndrome in children (MIS-C) or other serious hyperinflammatory conditions, given the combination of fever, rash, extreme leukocytosis (WBC 38,000), and elevated inflammatory markers. 1

Immediate Diagnostic Priorities

Tier 1 Screening (Urgent)

  • SARS-CoV-2 testing is mandatory - obtain both PCR and serology immediately, as MIS-C is temporally associated with COVID-19 and represents a life-threatening complication 1
  • Complete the inflammatory workup - you already have WBC and CRP; immediately add ESR, complete metabolic panel (looking specifically for hyponatremia, hypoalbuminemia, elevated creatinine, and liver enzyme abnormalities) 1, 2
  • Assess for lymphopenia, thrombocytopenia, or neutrophilia on the differential count, as these support MIS-C diagnosis 1

Critical Clinical Assessment

Admit this child immediately if ANY of the following are present: 1

  • Abnormal vital signs (tachycardia, tachypnea)
  • Any degree of respiratory distress
  • Neurologic changes (altered mental status, confusion, headache, focal deficits)
  • Signs of dehydration or shock
  • Abdominal pain or gastrointestinal symptoms

The CRP of 4 mg/dL is elevated but below the highly concerning threshold of >10 mg/dL that typically characterizes severe MIS-C; however, the extreme leukocytosis (38,000) is highly abnormal and demands urgent investigation 1

Tier 2 Evaluation (Hospital-Based)

Cardiac Assessment (Non-Negotiable)

  • EKG and echocardiogram are mandatory - MIS-C causes left ventricular dysfunction in 20-55% of cases and coronary artery abnormalities in ~20% of cases 1
  • Troponin T and BNP/NT-proBNP levels - highly elevated BNP may identify cardiac involvement even before clinical manifestations 1, 2
  • Monitor for arrhythmias - atrioventricular block occurs in up to 20% of MIS-C cases 1

Extended Laboratory Panel

  • D-dimer, ferritin, LDH, procalcitonin - these are frequently elevated in MIS-C and help distinguish from other conditions 1, 2
  • Blood cultures and evaluation for bacterial sepsis - the extreme leukocytosis could represent overwhelming bacterial infection, which must be excluded 3, 4
  • Albumin level - hypoalbuminemia is common in MIS-C and indicates more severe systemic inflammation 1, 2

Differential Diagnosis Considerations

MIS-C vs. Kawasaki Disease

MIS-C differs from classic Kawasaki disease in several key ways: 1

  • Broader age range (MIS-C affects older children more commonly)
  • More prominent gastrointestinal and neurologic symptoms
  • Higher likelihood of shock and cardiac dysfunction (arrhythmias, ventricular dysfunction)
  • More common in African, Afro-Caribbean, and Hispanic children; less common in East Asian descent

Other Critical Diagnoses to Exclude

  • Bacterial sepsis or toxic shock syndrome - the WBC of 38,000 with fever and rash could represent overwhelming bacterial infection requiring immediate antibiotics 3, 5
  • Acute leukemia - extreme leukocytosis in a child with fever requires peripheral blood smear examination to exclude blast cells 2
  • Drug-induced neutrophilic dermatosis (Sweet syndrome) - obtain medication history, though this typically shows neutrophilia not this degree of leukocytosis 6

Treatment Algorithm

If MIS-C is Confirmed

First-line therapy consists of: 1

  • IVIG 2 gm/kg (based on ideal body weight; may divide over 2 days if cardiac dysfunction present)
  • Consider adding methylprednisolone 1-2 mg/kg/day if the child has concerning features (ill appearance, unexplained tachycardia, elevated BNP) even without shock

Intensification therapy for refractory disease: 1

  • Methylprednisolone IV 10-30 mg/kg/day OR
  • High-dose anakinra
  • Refractory disease = persistent fevers and/or ongoing significant organ involvement despite first-line therapy

Multidisciplinary Team Required

Immediate consultation with: 1

  • Pediatric rheumatology
  • Pediatric cardiology
  • Pediatric infectious disease
  • Pediatric hematology (given the extreme leukocytosis)

Critical Pitfalls to Avoid

  • Do not delay SARS-CoV-2 testing - MIS-C can occur 2-6 weeks after COVID-19 infection, and serology may be positive even when PCR is negative 1
  • Do not assume this is "just a viral rash" - the combination of extreme leukocytosis (38,000) with fever and rash represents a medical emergency until proven otherwise 5
  • Do not wait for all test results before admitting - this child meets criteria for immediate hospitalization based on marked elevation of inflammatory markers alone 1
  • Do not miss cardiac involvement - cardiac complications are the primary cause of morbidity and mortality in MIS-C, and early detection is critical 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Inflammatory Laboratory Workup

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Elevated Serum Protein in Pediatric Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Identifying the Probable Etiology of Acute Undifferentiated Fever through Inflammatory Markers.

The Journal of the Association of Physicians of India, 2024

Research

Evaluating the febrile patient with a rash.

American family physician, 2000

Research

Pemetrexed-induced Sweet Syndrome: First case report in the medical literature.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.